What is the appropriate meloxicam dosage for chronic osteoarthritis, rheumatoid arthritis, and acute pain, with adjustments for elderly or renal/hepatic impairment?

Meloxicam Dosage

For osteoarthritis and rheumatoid arthritis, start with meloxicam 7.5 mg once daily, which can be increased to 15 mg daily if needed; no dose adjustment is required for elderly patients or those with mild-to-moderate renal or hepatic impairment, though meloxicam should not be used for acute postoperative pain due to lack of efficacy evidence.

Standard Dosing by Indication

Osteoarthritis

• Start: 7.5 mg once daily
• Maximum: 15 mg once daily if 7.5 mg provides insufficient relief 1
• The 7.5 mg and 15 mg doses demonstrate statistically significant efficacy over placebo, with benefits evident after 2 weeks of treatment 1
• A 3.75 mg dose exists but does not consistently reach statistical significance for all endpoints 1

Rheumatoid Arthritis

• Dose: 7.5-15 mg once daily 2
• Meloxicam is more effective than acetaminophen for chronic inflammatory pain like rheumatoid arthritis 3

Acute Pain

• Do not use meloxicam for acute postoperative pain 4
• A Cochrane review found zero studies demonstrating efficacy in established acute postoperative pain, concluding its use in this indication is not justified 4

Special Populations

Elderly Patients

• No dose adjustment required 5, 6
• However, exercise particular caution due to increased risk of NSAID-related adverse events in older adults 3
• NSAIDs were implicated in 23.5% of hospitalizations for adverse drug reactions in older adults 3
• Consider starting at 7.5 mg daily in frail older persons, though this is based on general NSAID safety principles rather than meloxicam-specific pharmacokinetic requirements 3

Renal Impairment

• Mild renal impairment (CrCl 41-60 mL/min): No dose adjustment needed 7
• Moderate renal impairment (CrCl 20-40 mL/min): No dose adjustment needed 7
• The pharmacokinetic study showed that while total plasma concentrations were lower in moderate renal impairment, free (active) meloxicam concentrations remained similar across all groups due to altered protein binding 7
• Avoid in severe renal impairment and intravascularly depleted states (e.g., congestive heart failure) 3

Hepatic Impairment

• Moderate hepatic insufficiency: No dose adjustment required 5, 6
• This is based on short-term pharmacokinetic studies 5

Pharmacokinetic Advantages

Meloxicam's 20-hour half-life enables convenient once-daily dosing, which improves compliance compared to shorter-acting NSAIDs 5, 6. Substantial concentrations accumulate in synovial fluid, the site of action in chronic inflammatory arthropathies 6.

Critical Safety Considerations

Gastrointestinal Risk

• Meloxicam has lower GI toxicity than traditional NSAIDs but greater risk than highly selective COX-2 inhibitors 3
• In the 12-week OA trial, GI adverse events and dropout rates for meloxicam were comparable to placebo and lower than diclofenac 1
• Risk increases with concomitant low-dose aspirin for cardioprotection 3
• Consider gastroprotective agents, though they only reduce gastric (not intestinal) adverse events 8

Cardiovascular Risk

• All NSAIDs carry cardiovascular risk 8
• Meloxicam specifically shows elevated risk of hemorrhagic stroke (along with diclofenac) 8
• Increased risk of acute myocardial infarction and heart failure observed with all NSAIDs 8
• Use extreme caution in patients with cardiovascular disease 3

Renal Risk

• All NSAIDs can induce acute kidney injury 8
• Patients with hypertension, heart failure, and diabetes mellitus are at increased risk 8

Common Pitfalls to Avoid

1. Do not use for acute postoperative pain - there is no evidence of efficacy 4
2. Do not unnecessarily adjust doses in elderly or mild-to-moderate renal/hepatic impairment - pharmacokinetics remain stable 5, 7, 6
3. Do not ignore cardiovascular risk assessment - meloxicam carries specific hemorrhagic stroke risk 8
4. Do not assume COX-2 preferential selectivity eliminates all NSAID risks - GI protection is incomplete and other toxicities persist 3

Drug Interactions

Monitor closely when co-prescribing:

• Cholestyramine (reduces meloxicam absorption)
• Lithium (meloxicam increases lithium levels)
• CYP2C9 and CYP3A4 inhibitors (may increase meloxicam concentrations) 5

Administration Route

• Oral tablets: 7.5-15 mg once daily (standard)
• Rectal suppository: Same doses as oral 2
• Intramuscular: 15 mg (1.5 mL) for 3-5 days, followed by oral transition 9
• Intravenous formulations exist but are primarily studied for postoperative pain 9